Fate Therapeutics (FATE) Total Current Liabilities (2012 - 2026)

Fate Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• Quarterly Total Current Liabilities rose 8.98% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 million (up 8.98% YoY) and the FY2025 annual result came in at $36.1 million, down 6.36% from the prior year.
• Total Current Liabilities was $30.7 million for Q1 2026 at Fate Therapeutics, down from $36.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $114.1 million in Q4 2022 and bottomed at $28.1 million in Q3 2025.
• A 5-year average of $51.1 million and a median of $39.1 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 40.31% — and 2023, when it slumped 65.72%.
• Fate Therapeutics' Total Current Liabilities stood at $114.1 million in 2022, then slumped by 65.72% to $39.1 million in 2023, then retreated by 1.46% to $38.5 million in 2024, then declined by 6.36% to $36.1 million in 2025, then slipped by 14.92% to $30.7 million in 2026.
• Business Quant data shows FATE's Total Current Liabilities at $30.7 million in Q1 2026, $36.1 million in Q4 2025, and $28.1 million in Q3 2025.